It doesn’t appeal to the appetites of Big Pharma, either. Novartis quit the antibiotics field, selling off its infectious disease portfolio to Boston Pharma, further diminishing the number of players ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback